Phenotypes associated with this allele

• Allele Symbol: Cfhr1^em1Wli
• Allele Name: endonuclease-mediated mutation 1, Wei Li
• Allele ID: MGI:8276744
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Cfhr1^em1Wli/Cfhr1^em1Wli	C57BL/6-Cfhr1^em1Wli	MGI:8276750

Genotype
MGI:8276750

hm1

• Allelic Composition: Cfhr1^em1Wli/Cfhr1^em1Wli
• Genetic Background: C57BL/6-Cfhr1^em1Wli

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

immune system phenotype ( J:303926 )

♂N • no abnormalities in C3a, C5a or Factor H levels in 6-8 week old male mice

increased granulocyte number ( J:303926 )

• proportion of granulocytes are increased at 6h after LPS and EDTA challenge

decreased lymphocyte cell number ( J:303926 )

• mildly decreased at 6h after LPS and EDTA challenge

increased circulating interleukin-1 beta level ( J:303926 )

• at 3h after LPS and EDTA challenge

increased circulating tumor necrosis factor level ( J:303926 )

• at 3h after LPS and EDTA challenge

abnormal complement pathway ( J:303926 )

• increase in C3-activated fragment in serum following incubation with LPS

• increase in LPS-induced C3b deposition and C5a production

• enhanced alternative complement pathway activation in response to LPS treatment

increased circulating complement protein level ( J:303926 )

• increase in plasma C3a 3h after LPS and EDTA challenge

decreased complement C5 level ( J:303926 )

• levels of C5 decrease more significantly from 1h after LPS challenge compared to wild-type controls

increased complement C5 level ( J:303926 )

• shortly following LPS treatment compared to similarly treated wild-type controls

• increased C5a levels 3h after LPS and EDTA challenge

increased acute inflammation ( J:303926 )

• following LPS challenge

increased susceptibility to endotoxin shock ( J:303926 )

• survival time is significantly shorter and mortality rate higher following challenge with 10 mg/kg LPS

• median survival time is 30h compared to 35h in wild-type mice

• at 26h post LPS challenge 35% of mice had died compared to 14% of wild-type controls

• LPS-induced kidney injury is more severe, with increased tubular dilations, apoptosis, and necrosis

• increased renal fibrin deposition and plasma fibrin levels after LPS challenge

renal/urinary system

abnormal kidney physiology ( J:303926 )

• LPS-induced kidney injury is more severe, with increased tubular dilations, apoptosis, and necrosis

• increased fibrin deposition after LPS challenge

homeostasis/metabolism

increased circulating complement protein level ( J:303926 )

• increase in plasma C3a 3h after LPS and EDTA challenge

increased circulating interleukin-1 beta level ( J:303926 )

• at 3h after LPS and EDTA challenge

increased circulating tumor necrosis factor level ( J:303926 )

• at 3h after LPS and EDTA challenge

decreased complement C5 level ( J:303926 )

• levels of C5 decrease more significantly from 1h after LPS challenge compared to wild-type controls

increased complement C5 level ( J:303926 )

• shortly following LPS treatment compared to similarly treated wild-type controls

• increased C5a levels 3h after LPS and EDTA challenge

hematopoietic system

decreased erythrocyte cell number ( J:303926 )

• dramatically lower at 12 h after LPS challenge

increased granulocyte number ( J:303926 )

• proportion of granulocytes are increased at 6h after LPS and EDTA challenge

decreased lymphocyte cell number ( J:303926 )

• mildly decreased at 6h after LPS and EDTA challenge